Targeted Nanoboron Delivery Platform for Boron Neutron Capture Therapy in Refractory Solid Tumors

Area of Science:

• Oncology
• Nanomedicine
• Radiotherapy

Background:

• Boron Neutron Capture Therapy (BNCT) shows promise for refractory solid tumors but is limited by conventional boron agents' poor tumor selectivity and rapid clearance.
• Suboptimal pharmacokinetics of agents like BPA and BSH hinder effective clinical translation of BNCT.
• Developing advanced delivery systems is crucial to overcome these limitations in BNCT.

Purpose of the Study:

• To review the role of nanoengineered delivery platforms in enhancing BNCT for solid tumors.
• To analyze advanced targeting mechanisms and their impact on tumor boron accumulation and retention.
• To examine the integration of multimodal imaging for precision-guided BNCT.

Main Methods:

• Comprehensive analysis of nanoengineered delivery platforms: lipid-based, polymeric, inorganic, and biomimetic nanocarriers.
• Focus on advanced targeting mechanisms: passive EPR effect, active ligand/receptor engagement, and nuclear localization.
• Critical examination of multimodal imaging integration (PET, MRI) for dosimetry and treatment planning.

Main Results:

• Nanoengineered platforms significantly enhance tumor boron accumulation (T/N ratios of 6-17) and intratumoral retention.
• Advanced targeting strategies improve the selectivity and efficacy of boron delivery in preclinical models.
• Integration of PET and MRI enables real-time dosimetry and precision treatment planning for BNCT.

Conclusions:

• Nanoengineered delivery platforms are revolutionizing BNCT by overcoming pharmacokinetic limitations of conventional boron agents.
• The convergence of targeted nanomedicine, precision imaging, and immunomodulation creates a robust platform for BNCT.
• BNCT, enhanced by nanomedicine and imaging, is emerging as a clinically viable precision oncology strategy for refractory malignancies.